Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on June 12, 2025
Spring Bio Solution Melancarkan NCE Grid untuk Menyahkod Pemfailan Para IV dan Peluang Pemfail Pertama
GlobeNewswire
·
June 12, 2025
SOMERSET, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Spring Bio Solution, peneraju global dalam penyumberan komparator dan bekalan percubaan klinikal telah melancarkan NCE Grid, platform risikan NCE-1 percuma pertama di dunia—dibangunkan untuk menyahkod, …
ANI Pharmaceuticals Announces Presentation of New Preclinical Data
GlobeNewswire
·
June 12, 2025
PRINCETON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced new preclinical data on the use of Purified Cortrophin Gel (repository corticotropin injection USP) (Cortrophin Gel) in a mouse …
Positive PoNSTEP Study Results Presented at Consortium of Multiple Sclerosis Centers Annual Meeting
GlobeNewswire
·
June 12, 2025
-PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple Sclerosis- -Presentation of full PoNSTEP study results expanded upon top line data …
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström…
GlobeNewswire
·
June 12, 2025
Complete response achieved in CLL; overall objective response rate of 80.9% in CLL patients and 84.2% in patients with WM Bexobrutideg was well tolerated with no new safety signals observed with longer duration on study or higher doses Data reinforces …
American Journal of Respiratory and Critical Care Medicine Publishes Landmark Data on AeroPace® System's Breakthrough Results in Ventilator Weaning
GlobeNewswire
·
June 12, 2025
EXTON, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Lungpacer Medical, Inc., a pioneering medical device company focused on neurostimulation therapies for critical care patients, today announced the publication of pivotal clinical trial results in the American …
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
GlobeNewswire
·
June 12, 2025
– 26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population – – Robust responses observed across subgroups, regardless of co-mutations, number of prior lines of therapy, or prior venetoclax, within efficacy- …
Catheter Precision (VTAK) Reports Key Progress for the LockeT Product
GlobeNewswire
·
June 12, 2025
FORT MILL, S.C., June 12, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that LockeT …
Counslr Launches in Texas to Increase Access to Mental Health Support for Staff and Students
GlobeNewswire
·
June 12, 2025
NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Counslr, a leading B2B mental health and wellness platform, announced today that it has expanded its footprint into the State of Texas starting with a partnership with Colorado Independent School District (ISD) …
I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire
·
June 12, 2025
ROCKVILLE, Md., June 12, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (“I-Mab” or the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that on …
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
GlobeNewswire
·
June 12, 2025
Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in the execution of its oncology strategy Acquisition of CureVac will complement …
BioNTech kündigt strategische Transaktion zur Übernahme von CureVac im Rahmen eines öffentlichen Umtauschangebots an
GlobeNewswire
·
June 12, 2025
Die geplante Übernahme soll die Forschung, Entwicklung, Herstellung und Kommerzialisierung von mRNA-basierten Krebsimmuntherapie-Kandidaten stärken und ist ein weiterer wichtiger Meilenstein in der Umsetzung von BioNTechs Onkologie-Strategie Die Übernahme …
New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters Demonstrates Reduced Infection Rates Among ICU Patients
GlobeNewswire
·
June 12, 2025
WAYNE, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow™ Chlorhexidine-Impregnated Central …
MedRisk Welcomes Satish Narayanan as Chief Data Officer, Expanding Data and AI Capabilities
GlobeNewswire
·
June 12, 2025
KING OF PRUSSIA, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- MedRisk, a leading managed care organization focused on improving recovery and cost outcomes in casualty claims, announced today the appointment of Satish Narayanan as Chief Data Officer (“CDO”). In …
Gavin Gassen, M.D. Brings His Expertise to ENT and Allergy Associates’ Poughkeepsie Office
GlobeNewswire
·
June 12, 2025
Tarrytown, New York, June 12, 2025 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA), the largest ear, nose, throat, allergy, and audiology practice in the country, is proud to welcome Gavin M. Gassen, M.D., a board-certified Otolaryngologist and …
Levicept to Present Further Analysis from Phase II Trial of Novel Neurotrophin-3 Inhibitor, LEVI-04, at EULAR
GlobeNewswire
·
June 12, 2025
Significant and clinically meaningful improvement in pain, function, and other outcomes in people with knee osteoarthritis Rapid onset of action observed Improvement in function out of proportion to pain-relieving effects First-in-class novel biologic …
Enterome raises $19 million to fund clinical development of its OncoMimics™ immunotherapy to treat Follicular Lymphoma
GlobeNewswire
·
June 12, 2025
Proceeds to fund Phase 1/2 trial of EO2463 OncoMimics™, as a monotherapy or in combination, to treat multiple forms of indolent non-Hodgkin lymphoma (iNHL) $9 million from new investor The Institute for Follicular Lymphoma Innovation (IFLI) $10 million …
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
GlobeNewswire
·
June 12, 2025
Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports development of a novel, in vivo approach to …
SNIPR BIOME Announces First Patient Dosed in its Phase 1b Clinical Trial of SNIPR001 in Patients with Hematological Cancer
GlobeNewswire
·
June 12, 2025
COPENHAGEN, Denmark, June 12, 2025 (GLOBE NEWSWIRE) -- SNIPR Biome ApS (“SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for microbial gene therapy, today announced that the first patient has been dosed in its …
Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress
GlobeNewswire
·
June 12, 2025
Median duration of response in FELIX study now 42.6 months after an additional 11 months of follow up More than half of patients still in remission at 24 months 38% of ongoing responders did not receive any subsequent therapy by month 33 Results suggest a …
Diagonal Therapeutics to Present New Preclinical Data Demonstrating Disease-Modifying Potential of Receptor Clustering Antibody Approach in HHT at EHA 2025 Congress
GlobeNewswire
·
June 12, 2025
Results demonstrate potential of Company’s clustering antibody approach to address key challenges in HHT disease manifestations: restoring ALK1-mediated cellular signaling, preventing and reversing arteriovenous malformations, and preventing HHT-associated …